15-Deoxy-Δ12,14-prostaglandin J2 induces expression of 15-hydroxyprostaglandin dehydrogenase through Elk-1 activation in human breast cancer MDA-MB-231 cells

Mutation Research
Hye-Rim KimHye-Kyung Na

Abstract

Overproduction of prostaglandin E2 (PGE2) has been reported to be implicated in carcinogenesis. The intracellular level of PGE2 is maintained not only by its biosynthesis, but also by inactivation/degradation. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is the key enzyme that catalyzes the conversion of oncogenic PGE2 to a biologically inactive keto metabolite. In the present study, we demonstrate that 15-deoxy-Δ(12,14)-prostaglandin J2 (15 d-PGJ2), one of the terminal products of cyclooxygenase-2, updregulates the expression and the activity of 15-PGDH in human breast cancer MDA-MB-231 cells. By using deletion constructs of the 15-PGDH promoter, we have found that E-twenty six (Ets) is the most essential determinant for 15-PGDH induction. 15 d-PGJ2 induced phosphorylation of Elk-1, one of Ets transcription factor family members, in the nucleus. Knockdown of Elk-1 abolished the ability of 15 d-PGJ2 to upregulate 15-PGDH expression. Furthermore, 15 d-PGJ2-mediated activation of Elk-1 was found to be dependent on activation of extracellular-signal related kinase (ERK) 1/2. Treatment of U0126, a pharmacological inhibitor of MEK1/2-ERK, abolished phosphorylation and DNA binding of Elk-1 as well as 15-PGDH induction in 15 d-PGJ2...Continue Reading

References

Dec 10, 1972·The Journal of Vitaminology·M Kamimura
Oct 1, 1995·Journal of Lipid Mediators and Cell Signalling·C M Ensor, H H Tai
Jun 30, 1998·Trends in Biochemical Sciences·B WasylykA Gutierrez-Hartmann
Apr 20, 2001·The Journal of Cell Biology·A E AplinR L Juliano
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Feb 21, 2003·The Journal of Biological Chemistry·Scott T EblenMichael J Weber
Mar 13, 2003·International Journal of Gastrointestinal Cancer·Koji HashimotoB Mark Evers
Dec 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Sung-Hee ChangTimothy Hla
Nov 16, 2004·The Journal of Biological Chemistry·Michael G BacklundRaymond N DuBois
Dec 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Min YanSanford D Markowitz
Jan 11, 2005·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jose U Scher, Michael H Pillinger
May 19, 2005·Cancer Research·Dimitri LodyginHeiko Hermeking
Oct 11, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Arun Seth, Dennis K Watson
Mar 15, 2006·Current Pharmaceutical Design·H-H TaiY Ding
Jun 28, 2006·The Journal of Pharmacology and Experimental Therapeutics·Shougang Zhuang, Rick G Schnellmann
Aug 2, 2006·Proceedings of the National Academy of Sciences of the United States of America·Seung-Jae MyungSanford D Markowitz
Aug 4, 2006·Cancer Research·Ido WolfH Phillip Koeffler
Aug 11, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elisabetta PaceMark Gjomarkaj
Mar 27, 2007·Annals of the New York Academy of Sciences·Eun-Hee KimYoung-Joon Surh
Mar 28, 2007·Trends in Endocrinology and Metabolism : TEM·Arthur Gutierrez-HartmannAndrew P Bradford
May 8, 2007·Prostaglandins & Other Lipid Mediators·Hsin-Hsiung TaiYunfei Ding
Sep 5, 2008·PPAR Research·Saswati HazraSteven M Dubinett
Jan 8, 2009·International Journal of Cancer. Journal International Du Cancer·Srilatha SwamiDavid Feldman
Jul 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexandra ThielAri Ristimäki
Aug 20, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sung-Won ShinJoo-In Park
Nov 6, 2009·Molecular Cancer Therapeutics·Lyudmila N KaliberovaSergey A Kaliberov
Dec 18, 2009·Cell Cycle·Agatha SusilaCheng-Gee Koh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.